PTACH

CHF 121.00
In stock
CDX-P0063-M0055 mgCHF 121.00
CDX-P0063-M02525 mgCHF 485.00
More Information
Product Details
Synonyms NCH 51; Cpd 51; S-[6-(4-Phenyl-2-thiazolylcarbamoyl)hexyl] thioisobutyrate
Product Type Chemical
Properties
Formula C20H26N2O2S2
MW 390.56
CAS 848354-66-5
Source/Host Chemicals Synthetic.
Purity Chemicals ≥95% (HPLC)
Appearance White crystals.
Solubility Soluble in DMSO (25mg/ml).
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key MDYDGUOQFUQOGE-UHFFFAOYSA-N
Smiles CC(C)C(=O)SCCCCCCC(=O)NC1=NC(=CS1)C1=CC=CC=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively). Cell-permeable prodrug that is intracellularly converted to a potent HDAC inhibitor. Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group. Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells in vitro (EC50 = 1.1 - 9.1μM). Also reactivates latent HIV-1 gene expression.

Product References

(1) T. Suzuki, et al.; J. Med. Chem. 48, 1019 (2005) | (2) T. Sanda, et al.; Leukemia 21, 2344 (2007) | (3) T. Suzuki, et al.; Bioorg. Med. Chem. Lett. 17, 1558 (2007) | (4) A.F. Victoriano, et al.; FEBS Lett. 585, 1103 (2011)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.